- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$32.58 BnMarket Estimate, 2026
$34.11 BnMarket Forecast, 2034
$49.26 BnCAGR, 2026–2034
4.7%Executive Summary: North America In-Vitro Diagnostics (IVD) Market
- Market Scope: Comprehensive market analysis of the North American in-vitro diagnostics industry covering product types (instruments, reagents and kits, software), technologies (clinical chemistry, immunoassay, molecular diagnostics, hematology, microbiology), diverse clinical applications (diabetes, infectious diseases, oncology, cardiology), and country-level dynamics across the United States, Canada, and Mexico.
- Market Valuation: Valued at USD 32.58 billion in 2025, estimated at USD 34.11 billion in 2026, and projected to reach USD 49.26 billion by 2034, registering a steady CAGR of 4.7% (2026–2034).
- Primary Growth Drivers: Rising demand for early disease diagnosis, increasing prevalence of chronic and infectious conditions, widespread adoption of point-of-care (POC) testing devices, the shift toward personalized medicine, and robust private-public investments in hospital and diagnostic laboratory infrastructure.
Key Market Segment Metrics (2026–2034)
| Category | Leading Segment / Position | Growth Dynamics |
|---|---|---|
| By Product | Reagents and Kits (commands the largest share of routine testing and assay consumption) | Software solutions experiencing heightened deployment for AI-enabled laboratory analytics and workflow automation. |
| By Technology | Immunoassays and Molecular Diagnostics (lead due to high sensitivity in detecting infectious pathogens, cardiac markers, and oncology targets) | Advanced DNA sequencing and molecular diagnostic panels expanding rapidly. |
| By Application | Infectious Diseases, Oncology, and Diabetes (driven by high disease incidence and routine screening requirements) | Growing emphasis on companion diagnostics and preventive oncology screening. |
| By Country | United States (largest regional market holding the lion's share, supported by advanced healthcare infrastructure and stringent FDA regulatory pathways) | Canada is estimated to be the fastest-growing country market, exhibiting a healthy CAGR over the forecast period. |
Major Market Players & Market Structure
Market Structure: Highly competitive, consolidated medical technology landscape featuring global life sciences giants investing heavily in automated diagnostics, point-of-care connectivity, and next-generation sequencing platforms.
Key Companies: Abbott Laboratories, Johnson & Johnson, Siemens Healthcare, Becton Dickinson, Roche Diagnostics, Beckman Coulter Inc., bioMérieux, Ortho Clinical Diagnostics, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Sysmex Corporation, and Thermo Fisher Scientific, Inc.
North America In-Vitro Diagnostics (IVD) Market Size
The size of the North American in-vitro diagnostics market was valued at USD 32.58 billion in 2025. The North American market is estimated to exhibit a CAGR of 4.7% from 2026 to 2034 and be worth USD 49.26 billion by 2034 from USD 34.11 billion in 2026.
MARKET DRIVERS
The rising prevalence for early diagnosis of diseases, increasing incidences of infectious and chronic diseases, and adopting point-of-care testing devices for accurate results in very little time are majorly driving the growth of the North American In-Vitro Diagnostics Market. In addition, the trend towards personalized medicines, the rise in the investments in hospitals and clinics by government and non-government organizations, and growth in the scale of diagnostic centers, along with the increasing flow of patients, are expected to fuel the North American IVD market.
Adopting the latest technologies and launching innovative products favoring the end-users in the medical sector certainly create growth opportunities for the market. Along with this, rising awareness over the availability of different treatment procedures for various diseases among individuals and ongoing research on the development of new devices in concern towards people's safety and adequate support from the private sectors through investments are lavishing the market's demand in North America.
MARKET RESTRAINTS
However, the high installation and maintenance cost of the equipment used in the diagnostic centers is quietly restricting the demand of the in-vitro diagnostics market in North America. Lack of standardization is one more factor hindering the growth rate of the market. In addition, the absence of skilled people to operate the devices more accurately and analyze the reports has remained challenging for the market players. Frequent changes in economic strategies may also negatively impact the market's growth rate in North America.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| CAGR | 4.7% |
| Segments Covered | By Product, Technology, Application and Region |
| Various Analyses Covered | Global, Regional and Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Regions Covered | The United States, Canada, Mexico, Rest of North America. |
| Market Leaders Profiled | Abbott Laboratories, Johnson & Johnson, Siemens Healthcare, Becton Dickinson, Roche Diagnostics, Beckman Coulter Inc., bioMérieux, Ortho Clinical Diagnostics, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Sysmex Corporation, and Thermo Fisher Scientific, Inc. |
REGIONAL ANALYSIS
North America was the largest regional segment of IVD globally and held 37.3% of the global IVD market share in 2025, owing to the growing prevalence of chronic diseases such as cancer and respiratory diseases.
Within North America, the United States is the largest market for in-vitro diagnostics, while Canada is estimated to be the fastest-growing with a healthy CAGR. The United States has the largest In-Vitro diagnostics market in the world. Continuous awareness and product innovations are the factors behind the leading market. In the United States, section 210 of the Federal Food, Drug, and Cosmetic Act says that diagnostics products are medical devices and biological product subjects. The use of point-of-care (POC) diagnostics and the high occurrence of chronic diseases, heart diseases, asthma, diabetes, and COVID-19 in 2020 are majorly boosting the IVD market growth in the U.S. These diseases are responsible for the high mortality rate in the United States. The use of in-vitro diagnostics is feasible for managing chronic conditions. Furthermore, advances in DNA sequencing, growing demand for diagnostic devices, customer healthcare spending, and government funds will increase the growth of the U.S. in-vitro diagnostics market in the forecast period.
KEY MARKET PLAYERS
Some of the companies that are playing a dominating role in the North American in-vitro diagnostics (IVD) market include
- Abbott Laboratories
- Johnson and Johnson
- Siemens Healthcare
- Becton Dickinson
- Roche Diagnostics
- Beckman Coulter Inc.
- bioMérieux
- Ortho Clinical Diagnostics, Inc.
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Sysmex Corporation
- Thermo Fisher Scientific, Inc.
MARKET SEGMENTATION
This research report on the North American in-vitro diagnostics (IVD) market is segmented and sub-segmented into the following categories.
By Product
- Instruments
- Reagents and Kits
- Software
By Technology
- Clinical Chemistry
- Hematology
- Immunoassays
- Coagulation and Hemostasis
- Molecular Diagnostics
- Microbiology
- Other IVD technologies
By Application
- Diabetes
- Infectious Diseases
- Oncology/Cancer
- Cardiology
- Nephrology
- Autoimmune Diseases
- Drug Testing
- HIV
By Country
- The United States
- Canada
- Rest of North America